Several new potential therapeutic approaches have resulted from recent insights in NMO pathogenesis, including complement and neutrophil elastase inhibition [226] (eculizumab, sivelestat [235]), and the blocking of antibodies to AQP4 with monoclonal antibodies (aquaporumab), among others. Here, ELANE is linked to neuromyelitis optica.